Rivaroxaban Oral Tablet [Xarelto]
Phase 3
Rivaroxaban Oral Tablet [Xarelto] is one of 8 therapeutic programs targeting Kawasaki Disease. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
7 competitors in Kawasaki Disease
#DrugCompanyPhaseTrials
1Coumadin
AAbbott
Approved
Bayer Aspirin
BayerPhase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ivig
ArgenxPhase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Aspirin or Clopidogrel
SSunnybrook Health Sciences Centre
Phase 3
Rivaroxaban Oral Tablet [Xarelto]
CChildren's Hospital of Fudan University
Phase 3
Firsekibart
RRuijin Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]